No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
IPHA Innate Pharma
- 2.050
- -0.110-5.09%
Close Dec 20 16:00 ET
- 2.040
- -0.010-0.49%
Post 20:01 ET
169.71MMarket Cap-4.71P/E (TTM)
2.100High2.025Low48.48KVolume2.080Open2.160Pre Close100.13KTurnover0.09%Turnover RatioLossP/E (Static)82.78MShares3.51152wk High5.69P/B117.03MFloat Cap1.29052wk Low--Dividend TTM57.09MShs Float11.950Historical High--Div YieldTTM3.47%Amplitude1.290Historical Low2.065Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
ADRs Close Lower; Innate Pharma S.A. Declines 22%
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
ADRs End Higher; WISeKey International Holding Ltd. Climbs 139%
Innate Pharma Shares Are Trading Higher After the Company Announced Its TELLOMAK Phase 2 Trial of Lacutamab Demonstrated Significant Symptom Relief and Quality of Life Improvements.
H.C. Wainwright Maintains Innate Pharma(IPHA.US) With Buy Rating, Maintains Target Price $11.5
Heat List
US
Overall
Symbol
Price
% Chg
No Data